Ocugen Inc (OCGN) Stock
Key stats
- Market cap
- $325.87M
- Price / Earnings ratio
- -4.9x
- EPS (TTM)
- -$0.20
- Volume
- Loading
- 52-week high
- $2.73
- 52-week low
- $0.69
Source: third-party data provider, as of November 13, 2026
Compare with OCGN
Recent news
Ocugen Enters Exclusive OCU400 License Agreement With Celairis
Ocugen Enters Exclusive OCU400 License Agreement With Celairis
OCGN
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
OCGN
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
OCGN
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGNNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.77
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.04
- SMA 50
- $0.96
- Price above SMA 50
- EMA 50
- $0.96
- Price above EMA 50
- SMA 200
- $1.40
- Price below SMA 200
- EMA 200
- $1.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Ocugen Enters Exclusive OCU400 License Agreement With Celairis
Ocugen Enters Exclusive OCU400 License Agreement With Celairis
OCGNOcugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
OCGNOcugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
OCGNOCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
OCGN
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN
Ocugen Q2 Earnings Call Highlights
Ocugen Q2 Earnings Call Highlights
OCGN
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
OCGN
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
OCGN
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
OCGNNews tone: automated (AI) classification of the article's content, not a price prediction.
About Ocugen Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1964 |
| Ms. Rita Johnson-Greene M.B.A. | CFO & Principal Accounting Officer | 1977 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 1982 |
| Mr. Paul Staid | Executive Vice President of Operations | — |
| John Kouch J.D. | General Counsel | — |
| Mr. Chris Clark | VP of Corporate Communications | — |
| Ms. Kristen Craft | Head of People & Culture | — |
| Dr. Vijay Tammara Ph.D. | Chief Development Officer | 1960 |
| Dr. Mohamed Genead M.D., M.Sc. | Chief Medical Officer | — |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.77
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.04
- SMA 50
- $0.96
- Price above SMA 50
- EMA 50
- $0.96
- Price above EMA 50
- SMA 200
- $1.40
- Price below SMA 200
- EMA 200
- $1.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.50
- Average
- $9.50
- High
- $9.50
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -23.6 | -24.5 | ||||||||||
| 2022 | -24.8 | -9.0 | -7.6 | -33.6 | +1.3 | +4.6 | +6.6 | +2.4 | -32.1 | -3.4 | -8.2 | -14.5 |
| 2023 | +1.6 | -21.3 | -15.0 | -17.4 | -34.3 | +20.0 | +10.7 | -28.3 | -7.0 | -7.5 | +8.3 | +45.0 |
| 2024 | -18.2 | +77.4 | +70.8 | -14.3 | +24.5 | -8.8 | +15.3 | |||||
| 2026 | +12.4 | -3.4 | -23.3 | +11.7 | -16.9 | +6.4 | -22.6 | -30.0 | +33.3 |
